Clinical Evaluation of Investigational Multifocal Contact Lenses

NCT03059810 | Completed Results FDA Device

• 1 other identifier: CR-5903
• Study Type: interventional
• Target: 72
• Locations: 1 country
• Sites: 9

Brief Summary

3-visit dispensing study to evaluate the subjective feedback of a multifocal contact lens in a population of presbyopic patients. Subjects will wear the contact lenses for a total of 12-16 days.

Conditions

Visual Acuity

Outcome Measures

Primary Outcomes (1)

• Overall Vision

  Overall vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.

  12-16 Day Follow-up

Study Arms (1)

Participating Subjects

EXPERIMENTAL

Participating Subjects who are habitual soft contact lens wearers, aged 40 to 70 years of age, will be dispensed investigational contact lenses to be worn from 12-16 days, to include a total of 3 visits.

Device: etafilcon A

Interventions

etafilcon A DEVICE

Investigational Contact Lens

Participating Subjects

Eligibility Criteria

• Age: 40 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
• The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
• Healthy adult males or females that are at least 40 years of age and no more than 70 years of age.
• The subject must either be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or if not, respond positively to at least one symptom on the "Presbyopic Symptoms Questionnaire".(Appendix B).
• The subject is a current soft spherical or toric contact lens wearer (defined as a minimum of 6 hours of wear per day at least two days of the week for a minimum of 1 month prior to the study).
• The subject's refractive spherical component must be between +1.25 Diopters (D) to +3.75 D in each eye.
• The subject's refractive cylinder must be -1.00 D to -1.50 D in each eye.
• The subject's refractive cylinder axis must be 90°±30° or 180°±30° in each eye.
• The subject's ADD power must be in the range of +0.75 D to +2.50 D in each eye.
• The subject must have best corrected distance visual acuity of 20/20-3 or better in each eye.
• The subject must have a wearable pair of spectacles if required for their distance vision.

You may not qualify if:

• Ocular or systemic allergies or disease, or use of medication which might interfere with contact lens wear.
• Pregnancy or lactation.
• Currently diagnosed with diabetes.
• Infectious diseases (e.g. hepatitis, tuberculosis) or an immune-suppressive disease (e.g. HIV).
• Clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal staining, tarsal abnormalities or bulbar injection, or any other corneal or ocular abnormalities which would contraindicate contact lens wear.
• Entropion, ectropion, extrusions, chalazia, recurrent styes, dry eye, glaucoma, history of recurrent corneal erosions.
• Any previous, or planned, ocular or intraocular surgery (e.g.radial keratotomy, photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK), lid procedures, cataract surgery, retinal surgery, etc.).
• A history of amblyopia, strabismus or binocular vision abnormality.
• Any ocular infection or inflammation.
• Any ocular abnormality that may interfere with contact lens wear.
• Use of any ocular medication, with the exception of rewetting drops.
• History of herpetic keratitis.
• Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.

Sponsors & Collaborators

• Johnson & Johnson Vision Care, Inc.: lead

Study Sites (9)

EYE Center Optometric

Rocklin, California, 95677, United States

Location

Dr. Ted Brink & Associates

Jacksonville, Florida, 32225, United States

Location

Vistakon Research Clinic

Jacksonville, Florida, 32256, United States

Location

Golden Vision

Sarasota, Florida, 34232, United States

Location

Eye Associates of Winter Park

Winter Park, Florida, 32792, United States

Location

University of Indiana School of Optometry

Bloomington, Indiana, 47405, United States

Location

Sacco Eye Group

Vestal, New York, 13850, United States

Location

Optometry Group, PLLC

Memphis, Tennessee, 38111, United States

Location

Total Eye Care, PA

Memphis, Tennessee, 38119, United States

Location

Results Point of Contact

• Title: Thomas Karkkainen- SR PRINCIPAL RESEARCH OPTOMETRIST
• Organization: Johnson & Johnson Vision

TKarkkai@its.jnj.com

904 443-3402

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 16, 2017
• First Posted: February 23, 2017
• Study Start: January 27, 2017
• Primary Completion: April 25, 2017
• Study Completion: April 25, 2017
• Last Updated: December 24, 2019
• Results First Posted: December 24, 2019

Record last verified: 2019-12

Locations

US (9)